The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen

Journal of Obstetrics and Gynaecology

Volumn 39, Issue 8, 2019, Pages 1117-1122

  Philip, Sarah ^a,b   Taylor, Anthony H ^a   Konje, Justin C ^a,c   Habiba, Marwan ^a,d,e  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ROYAL BERKSHIRE HOSPITAL   (United Kingdom)

^c SIDRA MEDICAL AND RESEARCH CENTER   (Qatar)

^d Centre for Medicine   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Decidualisation; endometrium; IGFBP 1; levonorgestrel; Mirena ; tamoxifen

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; TAMOXIFEN; BIOLOGICAL MARKER; IGFBP1 PROTEIN, HUMAN; LEVONORGESTREL;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DECIDUALIZATION; ENDOMETRIUM BIOPSY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MIDDLE AGED; PRIORITY JOURNAL; AGED; BLOOD; BREAST TUMOR; CHEMISTRY; DECIDUA; DRUG EFFECT; ENDOMETRIUM; INTRAUTERINE CONTRACEPTIVE DEVICE; PATHOLOGY; PHYSIOLOGY; POSTMENOPAUSE;

AGED; BIOMARKERS; BREAST NEOPLASMS; DECIDUA; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 85067568061     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443615.2019.1587600     Document Type: Article

References (29)

1. Bell SC. 1990. Assessment of endometrial differentiation and function. British Medical Bulletin 46:720–732.
2. Carroll JS, Hickey TE, Tarulli GA, Williams M, Tilley WD. 2017. Deciphering the divergent roles of progestogens in breast cancer. Nature Reviews Cancer 17:54–64.
3. Chan SS, Tam WH, Yeo W, Yu MM, Ng DP, Wong AW, et al. 2007. A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women. BJOG: An International Journal of Obstetrics & Gynaecology 114:1510–1515.
4. Cohen I, Figer A, Altaras MM, Tepper R, Shapira J, Cordoba M, et al. 1996. Common endometrial decidual reaction in postmenopausal breast cancer patients treated with tamoxifen and progestogens. International Journal of Gynecological Pathology 15:17–22.
5. Cohen I, Shapira J, Altaras M, Cordoba M, Rosen D, Beyth Y. 1992. Endometrial decidual changes in a postmenopausal woman treated with tamoxifen and megestrol acetate. BJOG: An International Journal of Obstetrics and Gynaecology 99:773–774.
6. Colletti RB, Roberts JD, Devlin JT, Copeland KC. 1989. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Research 49:1882–1884.
7. Corley D, Rowe J, Curtis MT, Hogan WM, Noumoff JS, Livolsi VA. 1992. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstetrics and Gynecology 79:111–116.
8. Critchley HO, Wang H, Jones RL, Kelly RW, Drudy TA, Gebbie AE, et al. 1998a. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Human Reproduction 13:1218–1224.
9. Critchley HO, Wang H, Kelly RW, Gebbie AE, Glasier AF. 1998b. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Human Reproduction 13:1210–1217.
10. Dominick S, Hickey M, Chin J, Su HI. 2015. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database Systematic Reviews 12:CD007245.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), 2005. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717.
12. Fowler DJ, Nicolaides KH, Miell JP. 2000. Insulin-like growth factor binding protein-1 (IGFBP-1): a multifunctional role in the human female reproductive tract. Human Reproduction Update 6:495–504.
13. Gardner FJ, Konje JC, Bell SC, Abrams KR, Brown LJ, Taylor DJ, Habiba M. 2009. Prevention of tamoxifen induced endometrial polyps using a levonorgestrel releasing intrauterine system long-term follow-up of a randomised control trial. Gynecologic Oncology 114:452–456.
14. Hejmadi RK, Chaudhri S, Ganesan R, Rollason TP. 2007. Morphologic changes in the endometrium associated with the use of the mirena coil: a retrospective study of 106 cases. International Journal of Surgical Pathology 15:148–154.
15. Ingec M, Gursoy HG, Yildiz L, Kumtepe Y, Kadanali S. 2004. Serum levels of insulin, IGF-1, and IGFBP-1 in pre-eclampsia and eclampsia. International Journal of Gynaecology and Obstetrics: The Official Organ of the International Federation of Gynaecology and Obstetrics 84:214–219.
16. Lahteenmaki P, Rauramo I, Backman T. 2000. The levonorgestrel intrauterine system in contraception. Steroids 65:693–697.
17. Lazebnik N, Hill LM, Robinson TM. 1994. Transvaginal sonography in a woman treated with megestrol acetate for breast cancer. Journal of Ultrasound in Medicine 13:652–654.
18. Leao RBF, Andrade L, Vassalo J, Antunes A, Pinto-Neto A, Costa-Paiva L. 2013. Differences in estrogen and progesterone receptor expression in endometrial polyps and atrophic endometrium of postmenopausal women with and without exposure to tamoxifen. Molecular and Clinical Oncology 1:1055–1060.
19. Leu JI-J, George DL. 2007. Hepatic IGFBP1 is a prosurvival factor that binds to BAK, protects the liver from apoptosis, and antagonizes the proapoptotic actions of p53 at mitochondria. Genes & Development 21:3095–3109.
20. Lonning PE, Hall K, Aakvaag A, Lien EA. 1992. Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research 52:4719–4723.
21. Nasri MN, Shepherd JH, Setchell ME, Lowe DG, Chard T. 1991. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. BJOG: An International Journal of Obstetrics & Gynaecology 98:470–475.
22. Nuovo MA, Nuovo GJ, Mccaffrey RM, Levine RU, Barron B, Winkler B. 1989. Endometrial polyps in postmenopausal patients receiving tamoxifen. International Journal of Gynecologic Pathology 8:125–131.
23. Pakarinen P, Lahteenmaki P, Rutanen EM. 1999. The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstetricia et Gynecologica Scandinavica 78:423–428.
24. Pengdi Z, Xiaoqun L, Hongzhi L, Zhao G, Jie C, Ruhua X, et al. 1999. The effect of a levonorgestrel-releasing intrauterine device on human endometrial oestrogen and progesterone receptors after one year of use. Human Reproduction 14:970–975.
25. Powles TJ, Bourne T, Athanasiou S, Chang J, Grubock K, Ashley S, et al. 1998. The effects of norethisterone on endometrial abnormalities identified by transvaginal ultrasound screening of healthy post-menopausal women on tamoxifen or placebo. British Journal of Cancer 78:272–275.
26. Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukkainen T. 1986. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. International Journal of Gynecologic Pathology 5:235–241.
27. Sugita S, Morishita Y, Kano J, Furuya S, Shiba-Ishii A, Noguchi M. 2011. IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. Histopathology 58:729–738.
28. Thierry van Dessel HJ, Chandrasekher Y, Yap OW, Lee PD, Hintz RL, Faessen GH, et al. 1996. Serum and follicular fluid levels of insulin-like growth factor I (IGF-I), IGF-II, and IGF-binding protein-1 and -3 during the normal menstrual cycle. The Journal of Clinical Endocrinology & Metabolism 81:1224–1231.
29. Wathen NC, Campbell DJ, Patel B, Touzel R, Chard T. 1993. Dynamics of prolactin in amniotic fluid and extraembryonic coelomic fluid in early human pregnancy. Early Human Development 35:167–172.